Evidence map›Paper›PMID 33052455›Full record

ReviewDer Internist2020

[Tumor effects on the heart and circulation].

M S Anker, S Hadzibegovic, S von Haehling

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

M S AnkerMedizinische Klinik für Kardiologie, Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Deutschland. markus.anker@charite.de.
S HadzibegovicMedizinische Klinik für Kardiologie, Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Deutschland.
S von HaehlingKlinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen (UMG), Robert-Koch-Straße 40, 37075, Göttingen, Deutschland. stephan.von.haehling@med.uni-goettingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a result of the continuous development of modern cancer treatment, more cancer patients can be cured every year. However, since many patients experience cardiovascular problems before, during and after their cancer treatment, cardio-oncology is becoming increasingly important. Numerous therapies can cause cardiotoxicity, such as chemotherapy, immunotherapy, antibody therapy and radiotherapy. If these remain undetected, the patient may develop, e.g. heart failure or severe heart valve damage. The broad spectrum of cardiovascular comorbidities has become an immense challenge for cardiologists and oncologists. Cardio-oncology also deals with the effects that cancer has on the cardiovascular system. New research indicates that the tumor itself also has direct negative effects on the heart, mediated by messenger substances. Therefore, it is important to understand which cancer patients are at increased cardiovascular risk, thereby enabling the development of new therapeutic approaches in the long term to maintain mobility and improve patient prognosis.

Indexed as

CardiotoxicityAntineoplastic AgentsCardiovascular SystemHeartHeart DiseasesHumansMedical OncologyNeoplasmsAntineoplastic AgentsCardiotoxicityCardiovascular diseasesHeart rate variabilityResting heart rateTumour

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.